SEARCH

SEARCH BY CITATION

References

  • 1
    Kangas L, Nieminen AL, Blanco G, et al. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 1986; 17: 10913.
  • 2
    Kallio S, Kangas L, Blanco G, et al. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 1986; 17: 1038.
  • 3
    Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 931218.
  • 4
    Gams R. Phase III trials of toremifene versus tamoxifen. Oncology 1997; 11 ( Suppl 4): 228.
  • 5
    Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer 1997; 76: 2707.
  • 6
    Pyrhonen S, Ellmen J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56: 13343.
  • 7
    Zhou WB, Ding Q, Chen L, et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat 2011; 128: 62531.
  • 8
    Shibutani S, Ravindernath A, Terashima I, et al. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 2001; 61: 392531.
  • 9
    Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast 2006; 15: 14257.
  • 10
    Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyl tamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989; 49: 217583.
  • 11
    Murdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 70817.
  • 12
    Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 71825.
  • 13
    Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981; 256: 85968.
  • 14
    Lim YC, Desta Z, Flockhart DA, et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55: 4718.
  • 15
    Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 175864.
  • 16
    Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 1519.
  • 17
    Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxy tamoxifen. Drug Metab Dispos 2002; 30: 86974.
  • 18
    Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 106275.
  • 19
    Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 34026.
  • 20
    Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 309.
  • 21
    Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 6174.
  • 22
    Irvin WJ, Jr, Walko CM, Weck KE, et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 32329.
  • 23
    Berthou F, Dreano Y, Belloc C, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994; 47: 188395.
  • 24
    Notley LM, Crewe KH, Taylor PJ, et al. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its α-hydroxy and α,4-dihydroxy derivatives. Chem Res Toxicol 2005; 18: 161118.
  • 25
    Nomeir AA, Ruegg C, Shoemaker M, et al. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001; 29: 74853.
  • 26
    Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 46580.
  • 27
    Murdter TE, Kerb R, Turpeinen M, et al. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Hum Mol Genet 2012; 21: 114554.
  • 28
    Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588.
  • 29
    Kim J, Peraire C, Froelich J, et al. Cytochrome P450 inhibition and pharmacokinetic drug interactions with toremifene. In:Presented at the 16th North American Regional ISSX Meeting, Baltimore, MD, 2009.
  • 30
    Dahmane E, Mercier T, Zanolari B, et al. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4′-hydroxylated metabolites in breast cancer patients. J Chromatogr B: Anal Technol Biomed Life Sci 2010; 878: 340214.
  • 31
    Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 165462.
  • 32
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005; 97: 165262.
  • 33
    Suzuki N, Liu X, Laxmi YR, et al. Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen. Int J Cancer 2011; 128: 97482.
  • 34
    Laxmi YR, Liu X, Suzuki N, et al. Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions. Int J Cancer 2010; 127: 171826.
  • 35
    Wright JS, Shadnia H, Anderson JM, et al. A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds. J Med Chem 2011; 54: 43348.
  • 36
    Taras TL, Wurz GT, Linares GR, et al. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet 2000; 39: 32734.
  • 37
    Anttila M, Valavaara R, Kivinen S, et al. Pharmacokinetics of toremifene. J Steroid Biochem 1990; 36: 24952.
  • 38
    Wiebe VJ, Benz CC, Shemano I, et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 25: 24751.